Back to Careers

Biocom highlights backgrounds of Catalyst Award winners including CEO Hanadie Yousef

Back to Careers

As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!

Back to Careers

BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteins

Back to Careers

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development

Back to Careers

National Institute of Aging showcases Juvena Therapeutics

Back to Careers

Longevity Technology Spotlights the Early Beginnings and Future Vision of Juvena Therapeutics

Back to Careers

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging

Back to Careers

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Back to Careers

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.

Back to Careers

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1